169 related articles for article (PubMed ID: 31560296)
1. The Analysis of the Effects of Executive Functions, Working Memory and Other Factors on Medication Adherence in Elderly Men with Benign Prostatic Hyperplasia and Overactive Bladder Symptoms.
Kosilov K; Kuzina I; Kuznetsov V; Kosilova L; Ivanovskaya M; Kosilova E
Curr Aging Sci; 2020; 13(1):72-80. PubMed ID: 31560296
[TBL] [Abstract][Full Text] [Related]
2. Triple Therapy with Tamsulosin, Dutasteride, and Imidafenacin for Benign Prostatic Hyperplasia in Patients with Overactive Bladder Symptoms Refractory to Tamsulosin: Subgroup Analyses of the DIrecT Study.
Yamanishi T; Asakura H; Seki N; Tokunaga S
Urol Int; 2021; 105(9-10):817-825. PubMed ID: 33690238
[TBL] [Abstract][Full Text] [Related]
3. Influence of current state of executive function and working memory on adherence to antimuscarinic therapy in older women with OAB.
Kosilov K; Kuzina I; Kuznetsov V; Kosilova E
Eur J Obstet Gynecol Reprod Biol X; 2019 Oct; 4():100086. PubMed ID: 31517309
[TBL] [Abstract][Full Text] [Related]
4. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
6. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.
Kosilov K; Loparev S; Kuzina I; Shakirova O; Zhuravskaya N; Lobodenko A
Aging Male; 2017 Mar; 20(1):39-44. PubMed ID: 28074677
[TBL] [Abstract][Full Text] [Related]
7. Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin.
Kosilov K; Loparev S; Ivanovskaya M; Kosilova L
Aging Male; 2015 Mar; 18(1):44-8. PubMed ID: 25136746
[TBL] [Abstract][Full Text] [Related]
8. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
9. [Combination therapy of benign prostate syndrome/lower urinary tract symptoms].
Madersbacher S
Urologe A; 2013 Feb; 52(2):212-8. PubMed ID: 23340696
[TBL] [Abstract][Full Text] [Related]
10. Survey of overactive bladder symptoms influencing bother before and after treatment with tamsulosin hydrochloride in Japanese patients with benign prostatic hyperplasia.
Tsujimura A; Takao T; Miyagawa Y; Okuda H; Yamamoto K; Fukuhara S; Nakayama J; Ueda T; Kiuchi H; Hirai T; Tsujimoto Y; Miura H; Kanno N; Higashino M; Nakamura Y; Nishimura K; Nonomura N
Urology; 2011 Nov; 78(5):1058-62. PubMed ID: 21908025
[TBL] [Abstract][Full Text] [Related]
11. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
12. Latest treatment for lower urinary tract dysfunction: therapeutic agents and mechanism of action.
Yamaguchi O
Int J Urol; 2013 Jan; 20(1):28-39. PubMed ID: 23190275
[TBL] [Abstract][Full Text] [Related]
13. Effects of vibegron, a novel β
Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
[TBL] [Abstract][Full Text] [Related]
14. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
15. Management of Benign Prostatic Hyperplasia in Older Adults.
Woodard TJ; Manigault KR; McBurrows NN; Wray TL; Woodard LM
Consult Pharm; 2016; 31(8):412-24. PubMed ID: 27535076
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
Yamanishi T; Asakura H; Seki N; Tokunaga S
Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585
[TBL] [Abstract][Full Text] [Related]
17. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
18. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
19. Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement.
Wada N; Matsumoto S; Kita M; Hashizume K; Kakizaki H
Low Urin Tract Symptoms; 2015 Jan; 7(1):37-41. PubMed ID: 26663650
[TBL] [Abstract][Full Text] [Related]
20. Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?
Cornu JN; Grise P
Curr Opin Urol; 2016 Jan; 26(1):17-21. PubMed ID: 26574877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
